Şevki ADEM, Ayşe ŞAHİN YAĞLIOĞLU, İbrahim DEMİRTAŞ, Çağlar GüLER, Emine Elçin ORUÇ EMRE, Ayşegül KARAKÜÇÜK İYİDOĞAN, Bedriye Seda KURŞUN AKTAR

Synthesis and biological evaluation of novel chalcones bearing morpholine moiety as antiproliferative agents

In this research, a new series of (E) -3-(4-substitutedphenyl)-1-(4’-morpholinophenyl)prop-2-en-1-one derivatives 1–7 was synthesized, aiming to develop effective antiproliferative agents. The antiproliferative activities of compounds 1–7 were examined against HeLa and C6 cell lines at eight different concentrations using the BrdU ELISA assay. The activity results were compared with reference anticancer drug 5-fluorouracil (5-FU). Compound 1 had almost the same antiproliferative activity as 5-FU. Compounds 1–7 were found to have greater effects against the C6 cell line than the HeLa cell line. These compounds were also tested in order to determine their effects on enzyme activities. Compounds 2 and 3 exhibited strong activator characteristics against pyruvate kinase isoenzyme M2 (PKM2) with AC 50 values of 2.2 and 14.28 µM. Compounds 2, 3, and 7 acted as inhibitors with IC50 values in the range of 84.08–165.38 µM for carbonic anhydrase isoenzyme I (hCA I), and compounds 3 and 4 demonstrated inhibitory effects against carbonic anhydrase isoenzyme II (hCA II) with IC50 values of 108.11 and 112.52 µM, respectively. hCA II was activated by derivatives 1, 2, 6, and 7 with AC50 values in the range of 85.53–146.59 µM.

PDF

___

1. Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D. M.; Forman, D.; Bray, F. Int. J. Cancer 2015, 136, 359-386.
2. Shah, A.; Khan, A. M.; Qureshi, R.; Ansari, F. L.; Nazar, M. F.; Shah, S. S. Int. J. Mol. Sci. 2008, 9, 1424-1434.
3. Yadav, N.; Dixit, S. K.; Bhattacharya, A.; Mishra, L. C.; Sharma, M.; Awasthi, S. K.; Bhasin, V. K. Chem. Biol. Drug. Des. 2012, 80, 340-347.
4. Bano, S.; Javed, K.; Ahmad, S.; Rathish, I. G.; Singh, S.; Chaitanya, M.; Arunasree, K. M.; Alam, M. S. Eur. J. Med. Chem. 2013, 65, 51-59.
5. Bandgar, B. P.; Gawande, S. S.; Bodade, R. G.; Totre, J. V.; Khobragade, C. N. Bioorg. Med. Chem. 2010, 18, 1364-1370.
6. Sharma, H.; Patil, S.; Sanchez, T. W.; Neamati, N.; Schinazi, R. F.; Buolamwini, J. K. Bioorg. Med. Chem. 2011, 19, 2030-2045.
7. Mizuno, C. S.; Paul, S.; Suh, N.; Rimando, A. M. Bioorg. Med. Chem. Lett. 2010, 20, 7385-7387.
8. Pizzuti, L.; Piovesan, L. A.; Flores, A. F. C.; Quina, F. H.; Pereira, C. M. P. Ultrason. Sonochem. 2009, 16, 728-731.
9. Amir, M.; Javed, S. A.; Kumar, H. Med. Chem. Res. 2010, 199, 299-310.
10. Thanh, N. D.; Thanh Mai, N. T. Carbohydr. Res. 2009, 344, 2399-2405.
11. El Gaby, M. S. A.; Saleh, N. M.; Micky, J. A.; Ammar, Y. A.; Mohamed, H. S. A. Phosphorus Sulfur Silicon Relat. Elem. 2006, 181, 1655-1663.
12. Thirunarayan, G.; Renuka, V. J. Chil. Chem. Soc. 2014, 59, 2574-2581.
13. Zangade, S. B.; Jadhav, J. D.; Lalpod, Vibhute, Y. B.; Dawane, B. S. J. Chem. Pharml. Res. 2010, 2, 310-314.
14. Ferlay, J.; Soerjomataram, I.; Ervik, M.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.; Forman, D.; Bray, F. GLOBOCAN 2012 v1. 0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer, 2013.
15. Gey, G. Cancer Res. 1952, 12, 264-265.
16. Landry, J. J.; Pyl, P. T.; Rausch, T.; Zichner, T.; Tekkedil, M. M.; St¨utz, A. M.; Jauch, A.; Aiyar, R. S.; Pau, G.; Delhomme, N. G3-Genes Genom. Genet. 2013, 3, 1213-1224.
17. Karmakar, S; Olive, M. F; Banik, N. L. Neurochem Res. 2007, 32, 2235-2242.
18. Assadian, S; Aliaga, A; Del Maestro, R. F. Neuro-Oncology 2008, 10, 292-299.
19. Valable, S; Lemasson, B; Farion, R. NMR Biomed. 2008, 21, 1043-1056. 20. Valable, S; Barbier, E. L; Bernaudin, M. NeuroImage 2008, 40, 973-983.
20. Locasale, J. W.; Cantley, L. C. BMC Biol. 2010, 8, 88-90.
21. Vander Heiden, M. G. Nat. Rev. Drug. Discov. 2011, 10, 671-684.
22. Hamanaka, R. B.; Chandel, N. S. J. Exp. Med. 2012, 209, 211-215
23. Harris, I.; McCracken, S.; Mak, T. W. Cell. Res. 2012, 22, 447-449.
24. Mazurek, S.; Hugo, F.; Zwerschke, W. Atlas Genet. Cytogenet. Oncol. Haematol. 2009, 13, 276-281.
25. Wu, S.; Le, H. Acta Biochim. Biophys. Sin. 2013, 45, 27-35.
26. Supuran, C. T. Nat. Rev. Drug. Discov. 2008, 7, 168-181.
27. Okwu, D. E.; Ukanwa, N. Der. Chem. Sinica 2010, 1, 21-28.
28. Azev, Y. A.; D¨ulcks, T.; Gabel, D. Tetrahedron Lett. 2003, 44, 8689-8691.
29. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Adv. Drug Deliv. Rev. 1997, 23, 3-25.
30. Zhao, Y. H.; Abraham, M. H.; Le, J.; Hersey, A.; Luscombe, C. N; Beck, G.; Sherborne, B.; Cooper, I. Pharm. Res. 2012, 19, 1446-1457.
31. Kur¸sun, B. S.; Oru¸c-Emre, E. E.; Karaküçük İyidğan, A.; S¸ahin, A.; Tekin, S¸.; Demirta¸s, ˙I. Turkish Patent Institute Patent No: 2011/05601, 2011.
32. Gopalakrishnan, M.; Thanusu, J.; Kanagarajan, V.; Govindaraju, R. Med. Chem. Res. 2009, 18, 341-350.
33. Demirtas, I.; Sahin Yaglioglu, A. E. J. Chem. 2013, 2013, 1-6.
34. Sahin Yaglioglu, A.; Demirtas, I.; Goren, N. Phytochem. Lett. 2014, 8, 213- 219.
35. Wilbur, K. M.; Anderson, N. G. J. Biol. Chem. 1948, 176, 147-154.
36. Christofk, H. R.; Vander Heiden, M. G.; Harris, M. H.; Ramanathan, A.; Gerszten, R. E.; Wei, R.; Fleming, M. D.; Schreiber, S. L.; Cantley, L. C. Nature 2008, 452, 230-233.
37. Aslan, E.; Adem, S. J. Biochem. Mol. Toxic. 2015, 29, 109-113.